Comparative Pharmacokinetics of Vitamin K AntagonistsWarfarin, Phenprocoumon and Acenocoumarol

被引：0

作者：

Mike Ufer

机构：

[1] University Hospital Schleswig-Holstein,Institute of Pharmacology

[2] Karolinska University Hospital (Huddinge),Division of Clinical Pharmacology

[3] Karolinska Institute,Institute of Pharmacology

[4] University Hospital Schleswig-Holstein,undefined

来源：

Clinical Pharmacokinetics | 2005年 / 44卷

关键词：

Warfarin; Human Liver Microsome; Intrinsic Clearance; Phenprocoumon; Acenocoumarol;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Vitamin K antagonists belong to the group of most frequently used drugs worldwide. They are used for long-term anticoagulation therapy, and exhibit their anticoagulant effect by inhibition of vitamin K epoxide reductase. Each drug exists in two different enantiomeric forms and is administered orally as a race-mate. The use of vitamin K antagonists is complicated by a narrow therapeutic index and an unpredictable dose-response relationship, giving rise to frequent bleeding complications or insufficient anticoagulation. These large dose response variations are markedly influenced by pharmacokinetic aspects that are determined by genetic, environmental and possibly other yet unknown factors.

引用

页码：1227 / 1246

页数：19

共 50 条

[41] In AF or VTE, acenocoumarol or phenprocoumon dosing by genotype did not affect time in therapeutic range
Dunn, Andrew
ANNALS OF INTERNAL MEDICINE, 2014, 160 (06)
[42] Sensitive stereospecific determination of acenocoumarol and phenprocoumon in plasma by high-performance liquid chromatography
Rentsch, KM
Gutteck-Amsler, U
Bührer, R
Fattinger, KE
Vonderschmitt, DJ
JOURNAL OF CHROMATOGRAPHY B, 2000, 742 (01): : 131 - 142
[43] Effects of argatroban alone or in combination with Phenprocoumon or Acenocoumarol on aPTT and ecarin clotting time.
Harder, S
Breddinj, HK
Graff, J
Osakabe, M
Watanabe, H
BLOOD, 2002, 100 (11) : 92B - 92B
[44] THE EFFECT OF LIVER-CIRRHOSIS ON THE PHARMACOKINETICS OF PHENPROCOUMON
KITTERINGHAM, NR
BUSTGENS, L
BRUNDERT, E
MINESHITA, S
OHNHAUS, EE
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (01) : 65 - 70
[45] Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus. phenprocoumon
Fihn, SD
Gadisseur, AAP
Pasterkamp, E
van der Meer, FJM
Breukink-Engbers, WGM
Geven-Boere, LM
van Meegen, E
de Vries-Goldschmeding, H
Antheunissn-Anneveld, I
van't Hoff, R
Harderman, D
Smink, M
Rosendaal, FR
THROMBOSIS AND HAEMOSTASIS, 2003, 90 (02) : 260 - 266
[46] Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data
van Schie, Rianne M. F.
Wessels, Judith A. M.
le Cessie, Saskia
de Boer, Anthonius
Schalekamp, Tom
van der Meer, Felix J. M.
Verhoef, Talitha I.
van Meegen, Erik
Rosendaal, Frits R.
Maitland-van der Zee, Anke-Hilse
EUROPEAN HEART JOURNAL, 2011, 32 (15) : 1909 - 1917
[47] GAS-CHROMATOGRAPHIC DETERMINATION AND PHARMACOKINETICS OF PHENPROCOUMON
HENI, N
GLOGNER, P
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1973, : R29 - R29
[48] Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands
Zhang, Yumao
de Boer, Anthonius
Verhoef, Talitha I.
van der Meer, Felix J. M.
Le Cessie, Saskia
Maitland-van der Zee, Anke H.
THROMBOSIS RESEARCH, 2015, 136 (01) : 94 - 100
[49] Age-Stratified Outcome Of Genotype-Guided Dosing Algorithm For Acenocoumarol And Phenprocoumon
Zhang, Yumao
De Boer, Anthonius
Verhoef, Talitha I.
Van der Meer, Felix J. M.
Le Cessie, Saskia
Manolopoulos, Vangelis G.
Maitland-Van der Zee, Anke H.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 570 - 571
[50] Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon
Zhang, Y.
de Boer, A.
Verhoef, T. I.
van der Meer, F. J. M.
Le Cessie, S.
Manolopoulos, V. G.
Maitland-van der Zee, A. H.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (03) : 454 - 464

← 1 2 3 4 5 →